IBRUNITIME 25 (Iguratimod (25mg))

IBRUNITIME 25 Tablet is indicated for the management of rheumatoid arthritis. Its mechanism involves modulating immune responses that are irregular and inhibiting the production of inflammatory mediators that contribute to symptoms such as redness and swelling. This medication can be administered either with or without food based on personal preference. It is crucial to adhere to the prescribed dosage schedule and continue the treatment until a healthcare provider advises discontinuation, even if symptoms improve. Staying adequately hydrated during treatment is recommended to mitigate the risk of kidney stones. Among the notable side effects associated with this medication are issues related to liver function, instances of pneumonia, and discomfort in the upper abdomen. Should any of these adverse effects remain persistent or intensify, it is important to inform your healthcare provider. They may propose alternative medication options or adjust your current dosage to alleviate these symptoms. Prior to commencing treatment with IBRUNITIME 25, it is advisable to disclose any existing heart, kidney, or liver conditions, as well as a complete list of medications you are currently taking. Additionally, individuals who are pregnant or breastfeeding should seek guidance from their healthcare provider before beginning this therapy. Use this medicine only under medical supervision. Follow the dose and schedule exactly as advised. Do not stop abruptly without guidance. Keep a record of any unusual symptoms and share them with your clinician. Combine therapy with appropriate lifestyle measures and routine monitoring as recommended.